FDA Panel Rejects Novartis Drug for Heart Failure
Wall Street Journal
Novartis said it had presented its best evidence gathered thus far, but it plans to continue with the drug serelaxin because of the "urgent patient need." Drugs for acute heart failure have generally been very disappointing. The vote by the outside ...
Novartis Heart Failure Drug Fails to Win FDA Panel BackingBloomberg
FDA Advisory Panel Recommends Against Approval Of Novartis Heart Failure ...Forbes

all 31 news articles »